OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2025
(2)
2021
(2)
2024
(1)
2022
(1)
2014
(1)
2013
(1)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Not available
S-EPMC4159618
|
biostudies-literature
Cite
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Not available
S-EPMC4496027
|
biostudies-literature
Cite
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
Not available
S-EPMC12583412
|
biostudies-literature
Cite
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
Not available
S-EPMC11170452
|
biostudies-literature
Cite
CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative.
Not available
S-EPMC9305285
|
biostudies-literature
Cite
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.
Not available
S-EPMC8604729
|
biostudies-literature
Cite
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Not available
S-EPMC12120674
|
biostudies-literature
Cite
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Not available
S-EPMC3145073
|
biostudies-literature
Cite
Mapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets